Immunogenicity and Safety of Yellow Fever Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients After Withdrawal of Immunosuppressive Therapy

Yellow fever (YF) vaccine appears safe and immunogenic in selected hematopoietic stem cell transplant recipients. Persistent immunity to YF vaccine is observed in some patients vaccinated before transplantation and/or vaccinated with an immunized donor. Immunity to YF should be evaluated prior to va...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2018-01, Vol.217 (3), p.494-497
Main Authors: Sicre de Fontbrune, Flore, Arnaud, Cécile, Cheminant, Morgane, Boulay, Aude, Konopacki, Johana, Lapusan, Simona, Robin, Christine, Bernaudin, Françoise, Suarez, Felipe, Simon, François, Socié, Gérard, Colin de Verdière, Nathalie, Consigny, Paul-Henri
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Yellow fever (YF) vaccine appears safe and immunogenic in selected hematopoietic stem cell transplant recipients. Persistent immunity to YF vaccine is observed in some patients vaccinated before transplantation and/or vaccinated with an immunized donor. Immunity to YF should be evaluated prior to vaccination. Abstract As a live attenuated vaccine, yellow fever vaccine (YFV) is not routinely performed after allogeneic hematopoietic stem cell transplant (HSCT) despite it being the only efficient preventive therapy. We retrospectively identified 21 HSCT recipients immunized with YFV at a median of 39 months after HSCT and a median of 33 months after withdrawal of immunosuppression without any side effects. Eighteen evaluable patients had protective immunity after YFV. We also observed that a third of the recipients vaccinated with YFV before HSCT had persistent protective immunity after HSCT.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/jix564